CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2.
We investigated the effect of a synthetic cannabinoid, WIN 55,212-2 on excitatory postsynaptic currents (EPSCs) evoked by stimulation of Schaffer collaterals in CA1 pyramidal cells. Bath application of WIN 55,212-2 reduced the amplitude of EPSCs in dose-dependent manner tested between 0.01 nM and 30 microM. In rats and mice, this cannabinoid ligand inhibited excitatory synapses in two steps at the nM and muM concentrations. When the function of CB(1) cannabinoid receptors (CB(1)R) was impaired, either by the application of a CB(1)R antagonist AM251, or by using CB(1)R knockout mice, WIN 55,212-2 in microM concentrations could still significantly reduced the amplitude of EPSCs. WIN 55,212-2 likely affected the efficacy of excitatory transmission only at presynaptic sites, since both at low and high doses the paired pulse ratio of EPSC amplitude was significantly increased. The inactive enantiomer, WIN 55,212-3, mimicked the effect of WIN 55,212-2 applied in high doses. In further experiments we found that the CB(1)R-independent effect of 10 microM WIN 55,212-2 at glutamatergic synapses was fully abolished, when slices were pre-treated with omega-conotoxin GVIA, but not with omega-agatoxin IVA. These data suggest that, in the hippocampus, WIN 55,212-2 reduces glutamate release from Schaffer collaterals solely via CB(1)Rs in the nM concentration range, whereas in microM concentrations, WIN 55,212-2 suppresses excitatory transmission, in addition to activation of CB(1)Rs, by directly blocking N-type voltage-gated Ca(2+) channels independent of CB(1)Rs.
Németh
Beáta
B
Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u. 43, Budapest H-1450, Hungary.
Ledent
Catherine
C
Freund
Tamás F
TF
Hájos
Norbert
N
D000818:Animals; D000831:Animals, Newborn; D048588:Benzoxazines / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004347:Drug Interactions; D004558:Electric Stimulation; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects*; D006624:Hippocampus / Q000166:cytology*; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D009433:Neural Inhibition / Q000187:drug effects; D009474:Neurons / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000172:deficiency / Q000378:metabolism*
D048588:Benzoxazines; D002121:Calcium Channel Blockers; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C103505:AM 251; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
J Neurophysiol. 2000 Mar;83(3):1167-80
10712447
J Neurosci. 2000 Apr 1;20(7):2470-9
10729327
Eur J Neurosci. 2000 Sep;12(9):3239-49
10998107
Br J Pharmacol. 2000 Oct;131(4):663-5
11030713
J Neurosci. 2001 Jan 1;21(1):109-16
11150326
J Neurophysiol. 2001 Jan;85(1):468-71
11152748
J Physiol. 2001 May 1;532(Pt 3):731-48
11313442
Neuron. 2001 Aug 16;31(3):453-62
11516401
Neuroscience. 2001;106(1):1-4
11564411
J Neurosci. 2001 Dec 15;21(24):RC188
11734603
EMBO J. 2001 Dec 17;20(24):7033-40
11742980
J Neurosci. 2002 May 15;22(10):3864-72
12019305
Neuropharmacology. 2002 Sep;43(4):503-10
12367597
Learn Mem. 2003 Mar-Apr;10(2):116-28
12663750
J Neurosci. 2003 Jul 2;23(13):5906-18
12843295
Physiol Rev. 2003 Jul;83(3):1017-66
12843414
Eur J Neurosci. 2003 Aug;18(3):524-34
12911748
Eur J Neurosci. 2003 Aug;18(4):1017-20
12925027
Eur J Neurosci. 2003 Oct;18(7):1973-8
14622229
Neuropharmacology. 2004 Jan;46(1):115-25
14654103
Mol Pharmacol. 1995 Sep;48(3):443-50
7565624
J Neurosci. 1996 Jul 15;16(14):4322-34
8699243
Brain Res. 1998 Feb 2;783(1):77-84
9479052
J Physiol. 1998 Aug 1;510 ( Pt 3):867-79
9660899
J Neurosci. 1999 Jun 1;19(11):4544-58
10341254
J Neurosci. 1999 Aug 15;19(16):6795-805
10436037
J Neurosci. 2005 Mar 16;25(11):2874-84
15772347
Eur J Neurosci. 2005 Nov;22(9):2387-91
16262678
J Physiol. 2005 Dec 1;569(Pt 2):501-17
16179366
Neuroscience. 2005;136(3):811-22
16344153
Neuroscience. 2006;137(1):337-61
16289348
J Neurosci. 2006 Mar 15;26(11):2991-3001
16540577
Neuroscience. 2006;139(3):795-802
16527424
J Neurosci. 2006 May 24;26(21):5628-37
16723519
J Neurophysiol. 2006 Sep;96(3):1267-77
16738209
Eur J Neurosci. 2007 Apr;25(8):2445-56
17445240
Br J Pharmacol. 2007 Jun;151(4):551-63
17435795
J Neurosci. 2006 May 24;26(21):5794-9
16723537